1. Belgium Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
UCB S.A.

UCB S.A.

UCB.BR
UCB S.A.BE flagEuronext Brussels
251.90
EUR
+3.60
- -
47.95BMarket Cap
UCB S.A.
UCB.BR
(Euronext Brussels)

Recent

price

251.90

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
35.73
36.37
38.62
34.39
35.12
40.36
44.03
48.12
49.15
52.48
28.29
30.57
29.1
27.69
32.38
40.72
Revenue per Share
1.15
2.67
2.78
1.76
2.19
6.49
5.52
8
8.49
8.46
3.87
5.6
2.2
1.81
5.61
8.19
Basic EPS, GAAP
4.75
1.74
1.49
-0.61
4.11
1.04
3.07
7.63
7.94
6.28
3.87
5.61
3.94
2.35
4.84
9.69
Free Cash Flow per Basic Share
1.93
1.98
2.24
2.25
2.33
2.34
2.45
2.31
2.36
2.44
1.24
1.27
1.3
1.33
1.36
1.39
Dividend per Share
- -
29.3
29.7
27.55
26.41
30.35
34.65
40.48
46.62
53.03
31.99
33.31
33.99
34.68
38.92
45.65
Book Value per Share
-19.62
-18.19
-19
-18.49
-13.22
-7.01
-6.12
0.86
4.4
11.87
-3.52
0.29
-5.76
-2.69
2.55
12.25
Tangible Book Value per Share
90
89
90
91
95
96
94
94
94
94
189
189
190
190
190
190
Basic Weighted Avg Shares
3,218
3,246
3,462
3,132
3,344
3,876
4,147
4,530
4,632
4,913
5,347
5,777
5,517
5,252
6,152
7,741
Sales/Revenue/Turnover
14.51
13.52
13.72
10.95
12.23
18.5
23.37
24.57
22.82
21.49
19.45
22.88
12.71
12.05
13.75
25.89
Operating Margin (%)
255
246
230
238
220
250
232
234
288
313
354
323
589
691
641
627
Depreciation Expense
104
238
249
160
209
623
520
753
800
792
732
1,058
418
343
1,065
1,558
Net Income, GAAP
- -
3.86
13.31
44.63
5.41
26.06
26.05
22.06
19.7
15.21
13.52
13.87
17.81
22.22
8.43
14.49
Effective Tax Rate (%)
3.23
7.33
7.19
5.11
6.25
16.07
12.54
16.62
17.27
16.12
13.69
18.31
7.58
6.53
17.31
20.13
Profit Margin (%)
-122
94
14
79
-104
-223
-87
728
798
901
768
886
192
828
1,259
1,653
Working Capital
1,758
1,772
1,890
2,027
1,747
1,585
1,574
1,534
1,350
975
2,316
2,068
2,638
2,996
2,963
2,183
LT Debt
4,592
4,701
4,593
4,322
4,842
5,546
5,477
5,736
6,255
7,009
7,272
8,386
9,064
8,975
10,029
10,867
Total Equity
- -
6.26
6.14
2.71
5.28
6.71
9.04
11.61
11.09
11.03
9.72
11.02
5.11
4.09
6.13
12.94
Return on Invested Capital (%)
- -
11.31
8.22
5.3
7.42
13.42
11.53
15.47
14.84
13.57
10.15
12.74
5.36
4.8
12.08
15.62
Return on Capital (%)
7.91
18.2
9.44
6.19
8.32
22.95
16.83
21.29
19.5
16.93
13.3
17.15
6.56
5.27
15.24
19.39
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
7.09%
8.5%
8.36%
Free Cash Flow
52.66%
36.37%
100.22%
Net Income, GAAP
24.88%
44.58%
46.29%
Sales/Revenue/Turnover
7.51%
8.34%
25.83%
Total Cash Common Dividend
1.65%
2.36%
1.93%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
5,252
2024
- -
- -
- -
- -
6,152
2025
- -
- -
- -
- -
7,741

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
1.81
2024
- -
- -
- -
- -
5.61
2025
- -
- -
- -
- -
8.19

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
1.33
2024
- -
- -
- -
- -
1.36
2025
- -
- -
- -
- -
1.39
Similar Companies
COSCIENS Biopharma Inc. (CSCI)
BioMarin Pharmaceutical Inc. (BMRN)
Chabiotech Co.,Ltd. (085660.KQ)
Ascentage Pharma Group International (6855.HK)
HCW Biologics Inc. (HCWB)
Notable Labs, Ltd. (NTBL)
Business
UCB SA is a global biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines and solutions for people living with severe neurological and immunology diseases. The company operates through three main business segments: neurology, immunology, and established brands; it offers a portfolio of branded prescription products including Briviact (brivaracetam) and Vimpat (lacosamide) for epilepsy; Bimzelx (bimekizumab) for plaque psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa; Cimzia (certolizumab pegol) for ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, and polyarticular juvenile idiopathic arthritis; Evenity (romosozumab) for osteoporosis; Fintepla (fenfluramine) for Dravet syndrome and Lennox-Gastaut syndrome; Keppra (levetiracetam) for epilepsy; Nayzilam (midazolam nasal spray) for epilepsy; Neupro (rotigotine) for Parkinson's disease and restless legs syndrome; RYSTIGGO (rozanolixizumab-noli) for myasthenia gravis; and ZILBRYSQ (zilucoplan) for myasthenia gravis. UCB conducts operations in approximately 40 countries worldwide, including key markets in the U.S., Europe (such as Germany, France, Italy, U.K., Ireland, and Belgium), Japan, China, and others, with around 9,000 employees supporting its activities. Founded in 1928 and headquartered in Brussels, Belgium, at Allée de la Recherche 60, the company generated revenue of €6.1 billion in 2024. Recent strategic changes include the completion in November 2024 of the sale of rights to established brands Atarax and Nootropil for Europe and select countries in Latin America and Asia-Pacific to ADVANZ PHARMA, generating €64 million in net sales in 2023 for these products and enabling UCB to update its 2024 financial guidance to revenue near €6 billion and an adjusted EBITDA margin in the upper part of 23.0-24.5%; a carve-out in August 2024 of its mature business in China, with 100% ownership acquired by Mubadala Investment Company in partnership with CBC Group to reinforce long-term commitment in Asia; and a strategic executive leadership rotation announced in November 2025, effective January 1, 2026, appointing Fiona du Monceau as Chief Commercial Officer and Emmanuel Caeymaex as Head of Patient Evidence to drive future growth and innovation.